Name
DISCUSSION: Clinically applicable properties of degraders
Date & Time
Tuesday, February 16, 2021, 1:00 PM - 1:25 PM
Speakers
Shaomeng Wang - University of Michigan
Rhamy Zeid - C4 Therapeutics Inc
Manfred Koegl - Boehringer Ingelheim
Andrew Zhang - AstraZeneca
Shaomeng Wang Rhamy Zeid Manfred Koegl Andrew Zhang
Description

·· Crucial factors affecting SAR

·· What DMPK and in vivo properties make a drug-like, clinically applicable degrader?

·· Defining PK and PD evaluation strategies

·· How do you establish in vivo efficacy and oral bioavailability?

·· Degree to which half-life and plasma-protein binding makes a good degrader

Virtual Session Link
View Session